The company is developing treatments to address the genetic roots of mitochondrial dysfunction. 

The company has a program to develop innovative treatments for epilepsy.

The company is developing therapies to treat cognitive Deficits across Brain Disorders & During Aging

A biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for disease of protein misfolding

Arclight is building a portfolio of neurodegeneration companies to accelerate transformative neuroscience.

Serenis makes professional therapy accessible, affordable, and convenient — so anyone who struggles with life’s challenges can get help, anytime and anywhere.

Cadence Neuroscience is an early-stage company developing new medical device therapies for the treatment of epilepsy, central pain, and other neurological disorders.

Freya™ is a clinical-stage company taking an innovative approach to women’s health, with microbial immunotherapies aimed at relieving the chronic inflammation underlying a range of reproductive system diseases uniquely afflicting women.

Noctrix Health revolutionizes Restless Legs Syndrome treatment with clinically validated wearable therapeutics. Their mission is to provide a groundbreaking alternative to pharmaceuticals for better sleep in millions of RLS patients.

It is a clinical-stage biotechnology company developing therapies to treat patients with autoimmune and inflammatory diseases. 

A company treating the conditions of urge urinary incontinence and urinary urgency caused by overactive bladder(OAB) syndrome through neurostimulation therapies.

Nouscom is a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies using proprietary viral vectors with demonstrated high immunogenicity in patients.

Argobio creates and develops pioneering biotech spinouts with the support of Bpifrance, Kurma Partners, Evotec, Angelini Ventures, and the Institut Pasteur.

Extend is a technology transfer initiative created in partnership between CDP Venture Capital Sgr. Evotec and Angelini Ventures to advance the impact of breakthrough research.